Reported Earlier, Kyverna's Miv-Cel Meets All Primary And Secondary Endpoints In KYSA-8 Registrational Trial, Potentially First Approved Treatment For Stiff Person Syndrome
Single-dose of miv-cel achieved robust and durable improvements in mobility, reversed disability scores, and eliminated the need for chronic immunotherapies – outcomes not previously observed in SPS
Data underscore potential for miv-cel to become the first and only approved treatment for SPS, fundamentally changing the treatme
Login to comment